Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

05. Mai 2021 09:00 ET | Quelle: Longeveron

Longeveron Invited to Present at the Benzinga Global Small Cap Conference

Longeveron recently announced positive results from a Phase 1 study of Lomecel-B in Alzheimer's disease, and the completion of two Phase 2 clinical trials evaluating the safety and efficacy of...
05. Mai 2021 08:30 ET | Quelle: Achilles Therapeutics PLC

Achilles Therapeutics to present at the BofA Securities 2021 Virtual Healthcare Conference

LONDON, May 05, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
05. Mai 2021 08:12 ET | Quelle: AXIM BIOTECHNOLOGIES, INC

AXIM® Biotechnologies’ Manufacturing Partner Empowered Diagnostics Files for Approval for Use of Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations in Canada and the EU

SAN DIEGO, May 05, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological...
05. Mai 2021 08:05 ET | Quelle: Pliant Therapeutics, Inc.

Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel...
05. Mai 2021 08:00 ET | Quelle: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces First Patient Dosed in Pivotal Phase 3 Registration Study of SQ MarzAA in Individuals with Hemophilia A or B with Inhibitors

SOUTH SAN FRANCISCO, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the dosing of the first patient in the Crimson 1 Study, the Company's Phase 3...
05. Mai 2021 08:00 ET | Quelle: Eyenovia, Inc.

Eyenovia to Report First Quarter 2021 Results on Wednesday, May 12

NEW YORK, May 05, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array...
05. Mai 2021 08:00 ET | Quelle: PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals Announces Participation at the Bank of America Healthcare Conference

CRANBURY, N.J., May 05, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
05. Mai 2021 08:00 ET | Quelle: 89bio, Inc.

89bio to Present at Upcoming Investor Conferences

SAN FRANCISCO, May 05, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
05. Mai 2021 08:00 ET | Quelle: Celularity, Inc.

Celularity Enters into Multi-Year Strategic Partnership with Palantir Technologies

Celularity to leverage Palantir’s next generation software and computational capabilities with their deep cellular data set to accelerate research and development activities Partnership includes...
05. Mai 2021 07:30 ET | Quelle: Progenity, Inc.

Progenity Provides Key Update Regarding its Preecludia™ Test for Preeclampsia

SAN DIEGO, May 05, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...

Vorherige Seite

Nächste Seite